Surface Oncology, Inc. acquired Surface Oncology, Inc

Surface Oncology, Inc. -> Surface Oncology, Inc · $5.2831

Toripalimab combinations with these two new agents have the potential to expand tori use into highly prevalent tumor types including NSCLC and head and neck cancer, where it has already consistently shown clinically meaningful activity.” At the closing of the